<DOC>
	<DOCNO>NCT02134808</DOCNO>
	<brief_summary>The primary hypothesis compare placebo , 10g daily creatine monohydrate eight week associate significant increase frontal lobe phosphocreatine beta-nucleoside triphosphate ( β-NTP ) concentration . A secondary hypothesis decrease depressive symptom measure Children 's Depression Rating Scale-Revised ( CDRS-R ) Montgomery-Asberg Depression Rating Scale ( MADRS ) reciprocally correlate increase β-NTP concentration .</brief_summary>
	<brief_title>Creatine Augmentation Adolescent Females With Treatment-Resistant Major Depressive Disorder</brief_title>
	<detailed_description>The current protocol seek expand upon investigator previous work open recruitment pilot study creatine 10g daily vs. placebo treatment female adolescent SSRI-resistant MDD . The purpose pilot study twofold : A ) evaluate several aspect feasibility creatine supplementation treatment population ; B ) estimate effect size adjunctive creatine , inform design implementation potential future efficacy trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>MAJOR DEPRESSIVE DISORDER SUBJECTS 1 . Participants must female . 2 . Participants must able grant inform consent ( age &gt; 18 ) , parent/guardian permission plus participant assent ( age &lt; 18 ) . 3 . Participants must meet DSM criterion Major Depressive Disorder ( MDD ) , current mood state depress &gt; 2 week . 4 . Participants must age 12 21 . 5 . Current CDRSR raw score &gt; 40 MADRS score &gt; 25 ; CGIS score &gt; 3 . 6 . Participants may enrol individual and/or group psychotherapy , ongoing least 8 week . 7 . Participants must treatment SSRI least 8 week , last 4 dosage &gt; 20 mg per day fluoxetine equivalent , e.g . 20 mg per day paroxetine , 20 mg citalopram , 10 mg escitalopram , 100 mg sertraline . If participant attempt , could tolerate , dose comparable 20 mg fluoxetine , consider eligible . ( This definition `` Adolescent SSRI Resistant Depression '' modify NIHsponsored , $ 17 million TORDIA Randomized Controlled Trial [ http : //clinicaltrials.gov/ct2/show/NCT00018902 ] . 1 . Unstable comorbid medical , neurological , psychiatric disorder . 2 . Current DSM criterion substance abuse dependence ( except nicotine/cigarettes ) . 3 . Clinically significant suicidal homicidal risk . 4 . Preexisting renal disease . 5 . Proteinuria baseline urinalysis test . 6 . Pregnancy breastfeed . 7 . Sexually active unwilling practice contraception study . 8 . Contraindication magnetic resonance imaging ( e.g . ferromagnetic implant claustrophobic anxiety ) . 9 . History hypersensitivity creatine . 10 . History previous fail therapeutic trial creatine . 11 . Participants may outpatients inpatient , incarcerated person exclude study approve `` Research Involving Prisoners . '' Study Withdrawal Criteria : 1 . Withdrawal parental permission , participant inform consent participant assent . 2 . Onset psychotic disorder bipolar disorder . 3 . Intolerable , clinicallysignificant side effect creatine . 4 . Worsening depression , demonstrate increase CDRSR MADRS score &gt; 25 % baseline . 5 . Positive pregnancy test . 6 . A significant change participant 's medication psychotherapy treatment regimen report baseline/screening visit ( e.g . SSRI discontinue ) . 7 . Incarceration , study approve conduct `` Research Involving Prisoners . '' 8 . If clinicallysignificant intracranial lesion find Radiologist participant 's baseline brain scan , withdrawn study refer appropriate medical care . 9 . The principal investigator retains right withdraw participant study without permission , event unwilling unable maintain adherence research protocol . HEALTHY COMPARISON SUBJECTS 1 . Participants must able grant inform consent ( age &gt; 18 ) , parent/guardian permission plus participant assent ( age &lt; 18 ) . 2 . Participants must female . 3 . Participants must age 12 21 year . 4 . Participants must meet DSM criterion current psychiatric illness substance use disorder . 5 . Participants must CDRSR score &lt; 30 . 1 . Unstable medical neurological illness . 2 . Clinicallysignificant psychiatric substance use disorder . 3 . Pregnant subject , due unknown effect MRI/MRS scan fetus . In addition , woman childbearing potential unable unwilling practice contraception study exclude . Female participant childbearing potential must negative urine pregnancy test MRI/MRS scan . 4 . Participants contraindication MRI/MRS scanning , metallic implant . Study Withdrawal Criteria : 1 . Withdrawal parental permission participant assent . 2 . Onset psychotic disorder depression . 3 . Positive pregnancy test . 4 . A significant change participant 's medication psychotherapy treatment regimen report baseline/screening visit , unless direct principal investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Creatine</keyword>
	<keyword>Brain Chemistry</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Treatment Resistance</keyword>
	<keyword>Selective Serotonin Reuptake Inhibitor ( SSRI ) Resistance</keyword>
</DOC>